Antibe Therapeutics
(TSX) ATE
This security has been delisted. This page is retained for historical reference.
ATE News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowATE Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-40%
Return on Capital
-30%
Return on Assets
-28%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$20.55M
EBITDA
$19.19M
Operating Cash Flow
$16.30M
Capital Expenditure
$9.00K
Free Cash Flow
$16.31M
Cash & ST Invst.
$38.89M
Total Debt
$0.00
Antibe Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
11
N/A
Net Income
$4.21M
+2.4%
EBITDA
$4.60M
-9.4%
Quarterly Fundamentals
Net Cash
$24.91M
-41.2%
Accounts Receivable
$1.55M
+128.0%
Inventory
$1.38K
-99.8%
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-27.60%
N/A
Return on Invested Capital
-30.31%
N/A
Free Cash Flow
$3.85M
-6.3%
Operating Cash Flow
$3.85M
-6.7%